ArticlePloS one2017

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.

Jordan Amdahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.